13th AACR-JCA Joint Conference
From Cancer Discovery Science to Therapeutic Innovation
February 1-5, 2025 | Maui, HI

AACR American Association for Cancer Research
JCA 一般社団法人 日本癌学会 JAPANESE CANCER ASSOCIATION
2409026E

Abstracts to be Presented as Poster Presentations

Poster Session A
Sunday, February 2, 5:30-7:30 p.m.
Mondarchy 5-7

Cancer Evolution and the Tumor Microenvironment

A01 Development of a 3D layered co-culture model using primary cultures for drug sensitivity testing in personalized medicine. Yuki Takahashi. TOPPAN Holdings Inc., Tokyo, Japan.

A02 New Insights into Supersulfides: Their Role in Suppressing Antitumor Immunity. Madoka Kawaguchi. Department of Medical Biochemistry, Tohoku University Graduate School of Medicine, Sendai, Japan.

A03 Identifying centrosome-related mechanisms governing breast cancer metastatic behaviour in an in vitro vascularized system. Yaxin Guo. University of Toronto, Toronto, ON, Canada.

A04 Transforming growth factor-β signaling facilitates the progression of oral squamous cell carcinoma by triggering epithelial-mesenchymal transition and tumor angiogenesis. Haruka Ibi. Institute of Science Tokyo, Tokyo, Japan.

A05 Modulation of immune tumor microenvironment by inhibition of FGFR4 signal pathway in colon cancer. Ik-Joo Chung. Chonnam National University Medical School and Hwasun Hospital, Hwasungun, Korea.

A06 ARID1A mutation induces gastric carcinogenesis via the activation of type II immunity and PI3K/AKT pathway. Junya Arai. The Institute of Medical Science, Asahi Life Foundation, Tokyo, Japan.

A07 Targeting TGF-β with chimeric Fc receptors inhibits crosstalk between various components of tumor microenvironment. Katarzyna A. Inoue. Institute of Science Tokyo, Dept. of Biochemistry, Tokyo, Japan.

A08 Novel extrahepatic cholangiocarcinoma model with driver mutations and fibrotic microenvironment. Hiroko Oshima. Cancer Research Institute, Kanazawa University, Kanazawa, Japan.

A09 HER3/Akt/mTOR pathway promote metastasis through incresing the expression of CXCR4 in triple-negative breast cancer. Tomoya Takeda. Kindai University, Higashi-Osaka, Japan.

A10 Effects of interactions between glioblastoma cells and astrocytes on hydrogel-enhanced stemness induction. Yusuke Shirai. Faculty of Medicine, Hokkaido University, Sapporo, Japan.

13th AACR-JCA Joint Conference
From Cancer Discovery Science to Therapeutic Innovation
February 1-5, 2025 | Maui, HI

AACR American Association for Cancer Research
JCA 一般社団法人 日本癌学会 JAPANESE CANCER ASSOCIATION

2409026E

A11 Uveal melanoma with a commonly found mutation in GNA11 or GNAQ secretes VEGF to escape from the eyes into circulation. Kaori H. Yamada. University of Illinois at Chicago, Chicago, IL, United States.

A12 Tumor-promoting secretome from senescent CAFs in the steatotic liver tumor microenvironment. Naoko Ohtani. Osaka Metropolitan University, Graduate School of Medicine, Osaka, Japan.

A13 Breast cancer-associated transcriptomic profiles of lymphatic endothelial cells derived from axillary adipose tissue reflect lymphatic invasion status. Asumi Iesato. NEXT-Ganken program, Japanese Foundation for Cancer Research, Tokyo, Japan.

A14 Spatially Resolved Single-Cell Profiling of Advanced Urothelial Carcinoma Uncovers Extracellular Matrix–Mediated Immune Escape Driven by Local Cell-Cell Interactions. Tomohiro Iwasawa. Keio University School of Medicine, Tokyo, Japan.

A15 Taxane functions as a vascular disrupting agent, enhancing metastasis when combined with anti-angiogenic therapy. Erik Henke. Universität Würzburg, Würzburg, Germany.

A16 Single cell-based analysis of tumor microenvironmental heterogeneity in the progression of MASLD/MASH-HCC. Yoshiki Nonaka. Osaka Metropolitan University, Osaka, Japan.

A17 Vasorin/slit-like 2 protein is induced by transforming growth factor-beta 1 through TRPV4 signaling and accelerates cellular migration in gastric cancer cells. Yoko Yasuda. Kyushu University, Fukuoka, Japan.

A18 ICAM2-mediated mechanisms and therapeutic targeting of leptomeningeal metastasis in triple-negative breast cancer. Pei-Jung Lu. Institute of Clinical Medicine, National Cheng Kung University, Tainan, Taiwan (Greater China).

A19 The inter-lesion and intra-tumor heterogeneity of peritoneal metastasis differs between gastric, clear cell ovarian, and pancreatic cancers. Wei-Ting Hung. National Taiwan University, Taipei, Taiwan (Greater China).

A20 Multimodal Spatial Profiling Reveals Immune Suppression and Microenvironment Remodeling in Fallopian Tube Precursors to High-Grade Serous Ovarian Carcinoma. Tanjina Kader. Harvard Medical School, Boston, MA, United States.

A21 Hypoxia-induced Cystathonine gamma-lyase promotes tumor motility via upregulation of stem cell factor in non-small cell lung cancer. Yoko Kataoka. Shiga University of Medical Science, Otsu, Japan.

A22 RK-582, a tankyrase inhibitor enhances the antitumor potential of an anti-PD-L1 antibody through remodeling of the tumor immune microenvironment. Ayane Nakamura. Division of

13th AACR-JCA Joint Conference
From Cancer Discovery Science to Therapeutic Innovation
February 1-5, 2025 | Maui, HI

AACR American Association for Cancer Research
JCA 一般社団法人 日本癌学会 JAPANESE CANCER ASSOCIATION
2409026E

Molecular Biotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan.

A23 Spatial transcriptomic profiling in NF1-associated neurofibroma and malignant peripheral nerve sheath tumor lesions. Satoshi Kamio. Department of Musculoskeletal Oncology and Rehabilitation, National Cancer Center Hospital, Tokyo, Japan.

A24 Proteomics investigation of mechanosensing and mechanotransduction pathways in the maintenance of fibroblasts in the tumor microenvironment. Carlo Ramil. Merck & Co., Inc., Cambridge, MA, United States.

A25 CADM1 is a potential target for diagnosis and treatment of small cell lung cancer. Yoshinori Murakami. Department of Molecular Biology, Institute for Advanced Medical Sciences, Nippon Medical School, Tokyo, Japan.

A26 TRAIL resistance-mediated CD44 expression facilitates cancer stemness of colon cancer cells and lung metastasis of colon cancer in animal models. Se Lim Kim. Research Institute of Clinical Medicine of Jeonbuk National University, Biomedical Research Institute of Jeonbuk National University Hospital, Jeonju, Korea, Republic of.

A27 Uncovering the diversity of pancreatic cancer-associated fibroblasts. Keiko Shinjo. Nagoya University Graduate School of Medicine, Nagoya, Japan.

A28 β3 adrenergic receptor and ephrin B4: dual targets for therapeutic intervention in high-risk neuroblastoma. Rachele Amato. AOU Meyer IRCCS, Florence, Italy.

A29 Identification of novel markers in the subsets of endothelial cells undergoing partial endothelial-mesenchymal transition (EndoMT) in tumor microenvironment. Tetsturo Watabe. Institute of Science Tokyo, Bunkyo-ku, Japan.

A30 Losartan rewires ovarian cancer tumor-immune microenvironment and suppresses IGF-1 to amplify chemo-immunotherapy sensitivity. Lei Xu. Masssachusetts General Hospital, Boston, MA, United States.

A31 Characteristics of normoxic and hypoxic pancreatic cancer organoids, and their origin in heterogeneous mixture of basal-like/classical subtype cells defined by 3D-spatial Xenium analysis. Tatsuya ODA. University of Tsukuba, Tsukuba, Japan.

Cancer Genomics

A32 Personalized reference genome-based cancer genome analysis pipeline can comprehensively identify somatic mutations. Yoshitaka Sakamoto. Division of Genome Analysis Platform Development, National Cancer Center Research Institute, Tokyo, Japan.

13th AACR-JCA Joint Conference
From Cancer Discovery Science to Therapeutic Innovation
February 1-5, 2025 | Maui, HI

AACR American Association for Cancer Research

JCA 一般社団法人 日本癌学会 JAPANESE CANCER ASSOCIATION

2409026E

A33 Decreased GPX7 expression by its promoter methylation is associated with the development of pseudomyxoma peritonei. Kioyko Takane. The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.

A34 Allergy-mediated alterations in the epithelial and immune compartments of the murine esophageal landscape may protect against carcinogenesis. Anne D Fuller. Temple University, Philadelphia, PA, United States.

A35 Characterization of the chromosomal breakpoints in MDS with der(1;7)(q10;p10) using long-read sequencing technologies. Masahiro Sugawa. National Cancer Center, Tokyo, Japan.

A36 Postoperative circulating tumor DNA could be a predictive marker for local recurrence in early-stage papillary thyroid cancer with BRAF V600E. Ayaka Sato. Department of Breast and Endocrine Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

A37 Association of somatic genotypes with cancer cachexia risk: a population-scale analysis using longitudinal BMI data. Amy X. Xie. Memorial Sloan Kettering Cancer Center, New York, NY, United States.

A38 An insertion/deletion variant mediates breast cancer progression through the transcriptional overexpression of LINC00636 and CD47. Paola Betancur. UCSF, San Francisco, CA, United States.

A39 Identifying Novel Modifiers of EGFR Induced Tumorigenesis. Jana M Jajarmi. BC Cancer Research Centre, Vancouver, BC, Canada.

A40 Prognostic impact of chromosomal alterations in TP53 -mutant acute myeloid leukemia and myelodysplastic syndromes. June Takeda. National Cancer Center Research Institute, Tokyo, Japan.

A41 Spatial transcriptomics can illuminate unfamiliar insights into the gene expression profiles of rare prostate cancer subtypes. Ryuta Watanabe. Ehime University, Toon, Japan.

A42 Regulation of the ESR1 super-enhancer by ELEANOR2 non-coding RNA in ER-positive breast cancer with focal amplification. Maierdan Palihati. Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.

A43 A novel inflammation gene expression signature to predict cancer related fatigue. Jeremy McGuire. University of Rochester, Rochester, NY, United States.

A45 Recruitment of histone deacetylases is not necessary for the suppression of PAX5 transactivity by PAX5::CBFA2T3. Fumihiko Hayakawa. Nagoya University, Nagoya, Japan.

13th AACR-JCA Joint Conference
From Cancer Discovery Science to Therapeutic Innovation
February 1-5, 2025 | Maui, HI

AACR American Association for Cancer Research

JCA 一般社団法人 日本癌学会 JAPANESE CANCER ASSOCIATION

2409026E

A46 Histone deacetylase inhibitor modulates enhancers determining cellular identity in ER-positive breast cancer cells. Noriko Saitoh. The Cancer Institute of JFCR, Tokyo, Japan.

A47 Genomic profiling of circulating tumor DNA in ovarian cancer in Asia: NCCH1905/A-TRAIN study. Lin-Hung Wei. National Taiwan University Hospital, Taipei, Taiwan (Greater China).

A48 Spatial immunogenomic analysis of the transformation process in acquired cystic disease of the kidney. Jun Takahashi. Division of Cellular Signaling, National Cancer Center Research Institute, Tokyo, Japan.

A49 Development an Artificial Intelligence Model to Identify BRCA Mutations in Prostate Cancer Through prostate MRI images. Hyunho Han. Yonsei University College of Medicine, Seoul, Korea, Republic of.

A50 Comprehensive RNA profiling identifies novel druggable fusion genes and four-gene signature for predicting prognosis in lung adenocarcinoma of never or light smokers. Yuki Terashima. National Cancer Center Research Institute, Tokyo, Japan.

A51 Anatomical genomic and transcriptomic analyses of Helicobacter pylori-driven gastric transformation. Yosuke Tanaka. National Cancer Center Research Institute, Tokyo, Japan.

A52 Comparative Analysis of GenMine TOP Panel and Foundation One Panel in Detecting Actionable Gene Fusions in Sarcoma. Eisuke Kobayashi. Division of Musculoskeletal Oncology, National Cancer Center Hospital, Tokyo, Japan.

A53 Whole genome landscape of small cell lung carcinoma and large cell neuroendocrine carcinoma of the lung. Hisashi Hashimoto. Division of Cellular Signaling, National Cancer Center Research Institute, Tokyo, Japan.

A54 Statistical approaches to cancer preventive behavioral profiling. MinJae Lee. University of Texas Southwestern, Dallas, TX, United States.

Cancer Immune Interaction

A55 Nuclear PD-L1 facilitates inflammation mediated by the cGAS-STING pathway in response to DNA damage. Naoe Taira Nihira. Department of Translational Oncology, St. Marianna University Graduate School of Medicine, Kanagawa, Japan.